Lauren K. GreshamJetaime RossErnest B. Izevbigie
Evidence suggests that most chemotherapeutic agents are less effective as treatment in patients with estrogen receptor-negative (ER-) breast carcinomas compared to those with estrogen receptor-positive (ER+) breast carcinomas. Moreover, African American Women (AAW) is disproportionately diagnosed with ER- breast cancer compared to their white counterparts. Novel therapies effective against ER- breast carcinomas are urgently needed to ameliorate the health disparity. Previous reports show that low concentrations (microgram/ml) of water-soluble leaf extracts of a Nigerian edible plant, V. amygdalina (VA), potently retards the proliferative activities of ER+ human breast cancerous cells (MCF-7) in vitro in a concentration-dependent fashion. However, the anti-proliferative activities of VA in either ductal or ER- carcinoma cells have not been characterized. The exposure of BT-549 to increasing concentrations of VA (10, 100, and 1000 µg/mL) inhibited cell growth by approximately 14% (P
Mutasim M. KhalafallaEltayb AbdellatefHussien M. DaffallaAmr NassrallahKhalid M. Aboul-EneinDavid A. LightfootAlan CocchettoHany A. El‐Shemy
Paul W. C. GreenSteven R. BelmainPatrick A. NdakidemiIain W. FarrellPhilip C. Stevenson